What’s Happening at Grifols?
Grifols, a well‑known Catalan pharmaceutical company, has announced a change in its leadership. The Board of Directors appointed Ester Masllorens Llinàs as a new independent director. She takes over the seat that was previously held by Enriqueta Felip Font, who stepped down on June 19.
Who Is Enriqueta Felip Font?
- Role before leaving: Director and member of the Sustainability, Communication and Reputation Commission.
- Professional background: Oncologist (cancer doctor).
- Education: Medicine and Surgery degree from the Autonomous University of Barcelona (UAB); PhD in Medical Oncology also from UAB.
- Academic work: Associate professor at UAB (2010‑2019), then Professor of Medicine at the University of Vic, and since March 2024 a Full Professor of Medicine at UAB.
- Current job: Head of the Medical Oncology Service at Vall d’Hebron University Hospital and lead researcher for the Lung Cancer Group at the Vall d’Hebron Oncology Institute (VHIO).
Felip served on the board for seven years before resigning.
Meet the New Director: Ester Masllorens Llinàs
- Experience: Over 20 years working internationally in the pharmaceutical industry.
- Expertise: Strong background in research and development (R&D).
- New role: Independent director on Grifols’ Board of Directors.
- What “independent director” means: She does not have ties to the company’s management, which helps bring an outside perspective to decision‑making.
Why Does This Matter?
Leadership changes can shape a company’s direction. Bringing in someone with fresh international experience and deep R&D knowledge may help Grifols innovate new medicines and strengthen its global presence. At the same time, recognizing the contributions of long‑serving members like Felip shows appreciation for their expertise and dedication.
Conclusion
The swap at Grifols highlights how companies balance seasoned insight with new ideas. Enriqueta Felip Font’s seven‑year service in oncology and academia leaves a lasting impact, while Ester Masllorens Llinàs steps in with a global pharma perspective aimed at guiding the company’s future growth.
Reference: Source
Images Credit: www.diariodeibiza.es